DelveInsight Business Research LLP

DelveInsight’s “Dermatomyositis – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the dermatomyositis historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Highlights of the Dermatomyositis Market 

• The Key Companies working in the Dermatomyositis market include Priovant Therapeutics, Pfizer, AstraZeneca, Argenx, CSL Behring, Janssen, Merck and many others 

• The Key Therapies working in the Dermatomyositis market include OCTAGAM, Brepocitinib, ULTOMIRIS, Efgartigimod, PF-06823859, and many others.

Dermatomyositis Overview

Dermatomyositis is a rare autoimmune disorder characterized by muscle inflammation (myositis) and skin inflammation (dermatitis). Proximal muscle weakness is a hallmark feature, affecting muscles close to the trunk, such as those in the thighs and upper arms, including heliotrope rash (purplish discoloration around the eyes), Gottron’s papules (reddish bumps on knuckles), and photosensitive rash on sun-exposed areas. The onset of the disease is usually insidious or acute, with a waxing and a waning course. The signs and symptoms of dermatomyositis can appear suddenly or develop gradually over time. Individuals with dermatomyositis also develop characteristic skin changes that, in some cases, may precede muscle weakness. Systemic symptoms such as fever, malaise, and weight loss are also present. The disease has a systemic involvement, often affecting multiple organs and systems, leading to various symptoms and complications. It is a complex and heterogeneous condition in adults (ADM) and children (JDM). Dermatomyositis has a bimodal onset age distribution. Most cases of juvenile DM present between 5 and 14 years of age, and most adult DM in the fifth and sixth decades of life. The pathogenesis of juveniles and adults is presumably similar, but important differences exist in clinical manifestations, associated disorders, and outcomes.

Dermatomyositis  Epidemiology Insights

• In 2022, the total diagnosed prevalent cases of dermatomyositis were estimated to be approximately 71,351 cases in the 7MM. Among these, nearly 9% were juvenile, while 91% were adult diagnosed prevalent cases of dermatomyositis. These cases are projected to increase during the forecast period.

• In 2022, among the 7MM, the US accounted for the highest diagnosed prevalent cases of dermatomyositis, contributing nearly 54%, while Spain accounted for the least with nearly 4% of the total diagnosed prevalent cases.

• In the US, there were approximately 38,266 diagnosed prevalent cases of dermatomyositis in 2022. These cases are expected to increase by 2032.

• In 2022, Germany ranked first among EU4 and the UK, with approximately 5,280 diagnosed prevalent cases of dermatomyositis, followed by the UK and Italy with nearly 4,568 and 3,978 cases, respectively. The total cases in EU4 and the UK are expected to increase by 2032.

• In EU4 and the UK, among the age-specific diagnosed prevalent cases of dermatomyositis, the age group 60–79 years accounted for the highest number of cases, with nearly 9,181 cases, while 0–17 had the least cases in 2022. These cases are expected to increase by 2032.

• In the US, females had a higher preponderance of dermatomyositis than males. There were approximately 26,051 females diagnosed with dermatomyositis while nearly 12,215 males in 2022

• In EU4 and the UK, there were more mild diagnosed prevalent cases of dermatomyositis than moderate to severe. Germany had nearly 2,950 mild cases, while, approximately 2,329 diagnosed cases were moderate to severe, in 2022.

• According to Delveinsight’s estimates, in 2022, among the total diagnosed prevalent cases of dermatomyositis in the US, there were nearly 11,480 and 26,786 acute and chronic cases, projected to increase during the study period.

• In Japan, comorbidities-specific diagnosed prevalent cases, including ILD, CVD, cancer malignancy, and others (osteoporosis, dysphagia, Raynaud’s syndrome, calcinosis, etc.) accounted for nearly 2,462, 2,206, 511, and 7,269 diagnosed prevalent cases, respectively, in 2022. These cases are expected to change during the study period.

Click here to learn more about the Dermatomyositis Market Landscape

The Report Covers the Dermatomyositis  Epidemiology Segmented by:

• Dermatomyositis diagnosed cases 

• Dermatomyositis incident cases

• Dermatomyositis prevalent cases 

• Dermatomyositis treatment cases 

Dermatomyositis Market Outlook 

There is no cure for dermatomyositis; however, medication can reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient’s quality of life. The recent approval of OCTAGAM and the presence of several management guidelines, including the British Society for Rheumatology guideline, the Japanese Society of Rheumatology guideline, and others, have revolutionized the treatment landscape of dermatomyositis. Several other off-label medications, including corticosteroids, immunosuppressants, antimalarial drugs, antibiotics, and topical ointments, are combined to eliminate symptoms. Nonpharmacological management options include diet and physiotherapy; plasmapheresis, extracorporal photochemotherapy, and total body irradiation are adjunctive treatment methods in therapy-resistant dermatomyositis cases. Surgery is not typical for dermatomyositis; however, gastrotomy may be helpful for patients whose esophageal dysfunction has become severe, and surgical removal of calcinotic nodules, if present, may be done. Further, for ophthalmologic management of dry eye, preventive care like alterations of the local environment, patient education, dietary modification including fatty acid supplementation, addition of ocular lubricants of various types, and lid hygiene are considered.

Key Companies Working in the Dermatomyositis Market

• Priovant Therapeutics

• Pfizer

• AstraZeneca 

• Argenx

• CSL Behring

• Janssen

• Merck 

And many others 

Dermatomyositis Therapies Covered and Analyzed in the Report

• OCTAGAM

• Brepocitinib

• ULTOMIRIS

• Efgartigimod

• PF-06823859

And many others.

Learn more about the Key Companies and Emerging Therapies in the Dermatomyositis  Market

Table of Contents 

1. Key Insights 

2. Dermatomyositis Introduction 

3. Executive Summary of Dermatomyositis            

4. Disease Background and Overview

5. Epidemiology and Patient Population

6. Dermatomyositis Emerging Therapies

7. Dermatomyositis Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Dermatomyositis Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services